Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

645 public trials 88 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Active, Not Recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Blood and Marrow Transplant Program Palo Alto, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
  • MD Anderson Caner Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Wien Vienna, Austria
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Columbia University Irving Medical Center New York, United States
  • Mount Sinai Medical Center New York, United States
View Trial Details
Active, Not Recruiting

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Créteil Hopital Henri Mondor Créteil, France
  • Dijon CHU Hopital le Bocage Dijon, France
  • Clermont Ferrand CHU Estaing Estaing, France
  • Grenoble CHU Pontchaillou Grenoble, France
View all 38 locations
View Trial Details

Related conditions